Australia markets closed

Myriad Genetics, Inc. (0K3W.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
22.67-0.87 (-3.68%)
At close: 05:31PM GMT
Full screen
Previous close23.54
Open22.67
Bid0.00 x 0
Ask0.00 x 0
Day's range22.67 - 22.67
52-week range14.53 - 24.13
Volume2
Avg. volume210
Market cap16.601M
Beta (5Y monthly)2.00
PE ratio (TTM)N/A
EPS (TTM)-0.11
Earnings date27 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

    Management will also participate in two upcoming healthcare conferencesSALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the com

  • GuruFocus.com

    Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc

    On December 31, 2023, Glenview Capital Management, led by Larry Robbins (Trades, Portfolio), made a significant addition to its investment portfolio by acquiring 1,500,000 shares of Myriad Genetics Inc (NASDAQ:MYGN). The trade had a 0.65% impact on the portfolio, bringing the position to 2.29% of the portfolio and 5.97% of the company's shares.

  • GlobeNewswire

    Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

    Dr. Dallas Reed Myriad Genetics, Inc. today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brin